Browsing by Author Friedlander, Michael

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 55  next >
Issue DateTitleAuthor(s)Citation
2014Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)Boland, Amy; Chatfield, Mark; Gebski, Val; Grimison, Peter; Houghton, Baerin; Stockler, Martin; et al, Various; Friedlander, Michael; Gruney, H; Kichenadasse, G; Lewis, Craig; Rosenthal, M; Singhal, N; Thomson, D B; Toner, Guy C.; Vasey, P; Wong, S; Northern Clinical School: Medicine; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAccelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP), Annals of Oncology, vol.25, 1, 2014,pp 143-148
2013The acceptability, feasibility, and efficacy (Phase I/II Study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancerJuraskova, Ilona; Mireskandari, Shab; Cheah, Benjamin; Friedlander, Michael; Meiser, Bettina; Mok, Kelly; Peate, Michelle; Sherin, Jarvis; Psychology; PsychologyThe acceptability, feasibility, and efficacy (Phase I/II Study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer, Journal of Sexual Medicine, vol.10, 10, 2013,pp 2549-2558
2005Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC)Beale, Philip; Clarke, Simon; Friedlander, Michael; Mitchell, Philip; White, Saxon; Zalcberg, John; Goldstein, David; Michael, M; Central Clinical School: Medicine; Western Clinical School: Westmead Millennium Institute; School of Public Health: NH&MRC Clinical Trials Centre; Medicine Faculty Office; Medicine; School of Public Health: NH&MRC Clinical Trials CentreAddition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC), Journal of Clinical Oncology, vol.23,(No 16S (June 1 Supplement)),2005,pp 3581-3581
2006Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, Paul L.; Thomson, Jacquelyn A.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAddition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity., Clinical Colorectal Cancer, vol.6,(2),2006,pp 146-151
2011Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancerRussell, Peter; Friedlander, Michael; Grant, Peter Thomas; Hopper, John Llewelyn; Jenkins, M. A.; kConFab Investigators, .; Kiely, Belinda E; McLachlan, Sue Anne; Milne, R; Phillips, Kelly-Anne; Stanhope, L; Weideman, Prue C; Central Clinical School: PathologyAdequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer, Familial Cancer, vol.10, 3, 2011,pp 505-514
2010Assessing Health-Related Quality of Life in Gynecologic Oncology: A Systematic Review of Questionnaires and Their Ability to Detect Clinically Important Differences and ChangeButow, Phyllis; King, Madeleine; Luckett, Timothy; Paris, Tim; Friedlander, Michael; Psychology; Psychology; Psychology; PsychologyAssessing Health-Related Quality of Life in Gynecologic Oncology: A Systematic Review of Questionnaires and Their Ability to Detect Clinically Important Differences and Change, International Journal Of Gynecological Cancer, vol.20, 4,pp 664-684
2005Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.Beale, Philip; Clarke, Stephen; Friedlander, Michael; Goldstein, David; Michael, Michael; Mitchell, P.; White, Shane; Zalcberg, John; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteAustralian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients., British Journal of Cancer, vol.92,(5),2005,pp 832-837
2012BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupdeFazio, Anna; Emmanuel, Catherine; Alsop, Kathryn; Birrer, Michael; Bowtell, David D L; Dobrovic, Alexander; Fereday, Sian; Fox, Stephen B.; Friedlander, Michael; George, Joshy; Meldrum, Cliff; Mitchell, Gillian; Stewart, Colin; Webb, Penelope M.; Western Clinical School: Westmead Millennium Institute; Western Clinical School: Westmead Millennium InstituteBRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group, Journal of Clinical Oncology, vol.30, 21, 2012,pp 2654-2663
2008Cancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancerButow, Phyllis; Price, Melanie; Dawson, Sarah-Jane; Friedlander, Michael; Hopper, John L.; Jenkins, Mark; Lindeman, Geoffrey J; McKinley, Joanne M; McLachlan, Sue Anne; Phillips, Kelly-Anne; Weideman, Prue C; Psychology; PsychologyCancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer, Journal of Clinical Oncology, vol.26, 2, 2008,pp 225-232
2012Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort StudyBoyle, Frances; Hickie, Ian; Scott, Elizabeth; Wilcken, Nicholas; Bennett, Barbara; De Souza, P; Friedlander, Michael; Goldstein, David; Lloyd, Andrew R.; McCourt, Junie; Murie, Penelope; O'Malley, Linda; Toppler, Ruth; Webber, Kate; Northern Clinical School: Medicine; School of Medical Sciences: Brain & Mind Research Institute; School of Medical Sciences: Brain & Mind Research Institute; Western Clinical School: Medicine (Westmead)Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study, Journal of Clinical Oncology, vol.30, 15, 2012,pp 1805-1812
2011Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancerBrown, Christopher; Gebski, Val; Gurney, Howard; Lee, Chee; Lord, Sarah (Sally); Simes, Robert John; Bacon, M; Donadello, Nicoletta; Friedlander, Michael; Maenpaa, J; Meier, W; Petru, E; Pujade-Lauraine, Eric; Reed, N; Sorio, R; Tulunay, G; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreCarboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer, British Journal of Cancer, vol.105, 3, 2011,pp 360-365
2014Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needsBell, Melanie Lynn; Butow, Phyllis; deFazio, Anna; Friedlander, Michael; Price, Melanie; Webb, Penelope M; Psychology; Psychology; Western Clinical School: Westmead Millennium Institute; School of Public Health: NH&MRC Clinical Trials Centre; PsychologyCaring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs, Gynecologic Oncology, vol.132, 3, 2014,pp 690-697
2006Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomasStewart, Michael; Aghmesheh, Morteza; Buckley, Michael F; Dorum, Anne; Friedlander, Michael; Kaern, Janne; Nesland, Jahn M; Suo, Zhenhe; Tucker, Katherine M.; Mathematics & StatisticsChromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas, Pathology, vol.38,(2),2006,pp 145-151
2011Clinical Trials in Recurrent Ovarian CancerBeale, Philip; Alberts, David; Avall-Lundqvist, Elisabeth; Brady, Mark; et al, various; Friedlander, Michael; Harter, Philipp; Pignata, Sandro; Pujade- Lauraine, Eric; Sehouli, Jalid; Tinker, Anna; Trimble, Edward; Vergote, Ignace; Central Clinical School: MedicineClinical Trials in Recurrent Ovarian Cancer, International Journal Of Gynecological Cancer, vol.21, 4, 2011,pp 771-775
2013Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testingBarlow-Stewart, Kristine; Kasparian, Nadine; Friedlander, Michael; Gleeson, Margaret; Meiser, Bettina; Trainer, Alison; Tucker, Kathy; Watts, Kaaren; Northern Clinical School: Medicine; PsychologyCommunication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing, Oncology Nursing Forum, vol.40, 3, 2013,pp 275-283
2003A decision aid for women at increased risk for ovarian cancerKirk, Judy; Andrews, L.; Friedlander, Michael; Gaff, C; Meiser, Bettina; Phillips, Kelly-Anne; Reeson, E.; Tiller, K.; Tucker, M.; Western Clinical School: Westmead Millennium InstituteA decision aid for women at increased risk for ovarian cancer, International Journal Of Gynecological Cancer, vol.13,(1),2003,pp 15-22
2014Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian CancerButow, Phyllis; Friedlander, Michael; Gillies, Kim Michelle; King, Madeleine; Martyn, Julie; Mercieca-Bebber, Rebecca; O'Connell, Rachel; Sjoquist, Katrin; Stockler, Martin; Voysey, Merryn; Donovan, Heidi; Oza, Amit; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; Psychology; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreDevelopment of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer, International Journal of Gynecological Cancer, vol.24, 5, 2014,pp 865-873
2015Dry eyes and AIs: If you don't ask you won't find outBoyle, Frances; Inglis, Holly; Watson, Stephanie; Friedlander, Michael; Northern Clinical School: Medicine; Central Clinical School: Save Sight & Eye Health Inst.; Central Clinical School: Ophthalmology & Eye HealthDry eyes and AIs: If you don't ask you won't find out, The Breast, vol.24, 6, 2015,pp 694-698
2016The effect of pulmonary function testing on bleomycin dosing in germ cell tumoursGrimison, Peter; Roncolato, Felicia; Stockler, Martin; Chatfield, Mark; Friedlander, Michael; Gurney, Howard; Houghton, Baerin B; Rosenthal, Mark; Thomson, Damien; Toner, Guy; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreThe effect of pulmonary function testing on bleomycin dosing in germ cell tumours, Internal Medicine Journal, vol.46, 8, 2016,pp 893-898
2007The experience of cancer related fatigue and chronic fatigue syndrome: A qualitative and comparative study.Hickie, Ian; Lloyd, Andrew; Bennett, Barbara; Friedlander, Michael; Goldstein, David; Central Clinical School: Brain & Mind Research Institute; Medicine Faculty OfficeThe experience of cancer related fatigue and chronic fatigue syndrome: A qualitative and comparative study., Journal of Pain and Symptom Management, vol.34,(2),2007,pp 126-135